We were pleased to present at ASBRS2025 in Las Vegas, where we shared new clinical findings from the Digistain® programme.
Our presentation included an abstract evaluating Digistain®’s performance against an established comparator in metastasis-free survival for early-stage HR+ breast cancer patients. The findings were well received by the clinical and research community.
We look forward to sharing more detailed results in the coming weeks as peer review progresses. Breast cancer prognostics continues to evolve, and we’re proud to be contributing to that progress.
